Avricore Health is now ranked among the top 10 undervalued stocks in the Medical Diagnostics & Research industry on the Toronto Stock Exchange or TSX Venture Exchange.
- A stock is considered undervalued if it trades at a discount to its valuation – a calculation used to determine the intrinsic (true) worth of a company
- Valuation methodology provided by Stockcalc (see below)
Medical Diagnostics & Research: Companies that provide laboratory testing services through imaging and other diagnostic services to the medical industry.
Stocks in this category are held primarily for capital appreciation.
| Symbol | Name | Close Price ($) | Valuation ($) | Difference | Average Vol (30D) | Market Cap ($M) | Yield (%) | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
| AVCR | Avricore Health | 0.06 | 0.11 | 0.05 (95.1%) | 84333 | 5.5 | 0.0 | 0.0 |
All data provided as of June 16, 2025.
The list is sorted by stocks with the greatest percentage difference between valuation and price.
Avricore Health
Avricore Health Inc is a Canada-based company. The company is involved in the business of health data and point-of-care technologies. The Company has only one segment, being the HealthTab - Point of Care Business in Canada. The Company's revenues are generated from operating leases of the POCT system and the sale of testing panels.
Avricore Health is listed under AVCR on the TSX Venture Exchange.
Stockcalc
StockCalc is a Canadian fintech company specializing in fundamental valuations for North American stocks and ETFs.
Stockcalc valuations (https://www.stockcalc.com/Resources) can help determine if a stock is undervalued. Stockcalc’s Weighted Average Valuation (WAV) is based on a proprietary calculation using model and analyst inputs, including:
- Discounted Cash Flow (DCF)
- Price & Other Comparables
- Multiples
- Adjusted Book Value (ABV)
- Analyst Consensus
Artificial Intelligence at Report on Business
Report on Business scans market data using algorithms to process large quantities of information. The results are specialized reports produced through automation. Ongoing ROB project experiments that leverage artificial intelligence include valuation screens across 14 categories and end-of-day Closing Summary reports for all North American securities.